Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GD-N2203
- Development stage
- Unknown
- Lead developer
- Sichuan Gooddoctor Panxi Pharmaceutical
- Modality
- Small Molecules
- Administration
- Rectal
01
Overview
GD-N2203 is a chemical drug under development by Sichuan Gooddoctor Panxi Pharmaceutical. It is being investigated as an enema solution for the treatment of immune system diseases and digestive system disorders, with a primary focus on inflammatory bowel diseases. The drug is currently in Phase 1 clinical trials, where its safety, tolerability, and pharmacokinetic characteristics are being evaluated in healthy adult subjects. The specific mechanism of action and molecular target have not been disclosed.
- Other names
- GD-N2203GD-N-2203GD-N 2203
Beyond the preview
Go deeper on GD-N2203.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GD-N2203.